At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 107 enrolled
Drug / intervention
PAD inductiondrug
Likely dose
PAD induction 1.3 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance
In Brief
A Phase 2 clinical trial evaluating PAD induction for Multiple Myeloma. Completed, enrolled 107 participants across 16 sites.
Detailed Summary
The purpose of this study is to determine efficacy of treatment with bortezomib (in combination with doxorubicin and dexamethasone) in previously untreated patients with Multiple Myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedMar 2009
Primary CompletionMar 2011
Study CompletionNov 2011
TodayJul 2026
First PostedMar 31, 2009
Enrollment StartJan 1, 2009
Primary CompletionMar 1, 2011
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 17.3 years ago
Interventions
PAD inductiondrug
Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)